Chemotherapy-induced Nausea and Vomiting Drugs Industry Research Business Report 2024: Market to Surpass $5 Billion by 2030 - Antiemetic Drug Formulations, & Quality of Life Focus Drives D...
Baxter International Inc. (BAX)
Last baxter international inc. earnings: 4/30 07:15 am
Check Earnings Report
US:NYSE Investor Relations:
investor.baxter.com
Company Research
Source: Yahoo! Finance
a CAGR of a 5.3%. The Neurokinin NK1 Receptor Antagonist segment is also set to grow at 5.8% CAGR over the analysis period. Gain insights into the U.S. market, which was estimated at $983.5 Million in 2023, and China, forecasted to grow at an impressive 4.9% CAGR to reach $809.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Chemotherapy-induced Nausea and Vomiting Drugs Market Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-induced Nausea and Vomiting Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Chemotherapy-induced Nausea and Vomiting Drugs was estimated at US$3.6 Billion in 2023 and is projected to reach US$5.1 Billion by 2030, growing at a CAGR of 5.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. T
Show less
Read more
Impact Snapshot
Event Time:
BAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAX alerts
High impacting Baxter International Inc. news events
Weekly update
A roundup of the hottest topics
BAX
News
- Peritoneal Dialysis Market Research 2024-2034: Growing Prevalence of Chronic Diseases Underscores Need for Dialysis Innovations [Yahoo! Finance]Yahoo! Finance
- Baxter to Present at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- The Global Market for Motion Sickness Treatment, 2024-2030: Increasing Preference for OTC Solutions Strengthens Business Case [Yahoo! Finance]Yahoo! Finance
- Moon Surgical Appoints Chris Toth as Independent Board Member Ahead of Commercial Acceleration [Yahoo! Finance]Yahoo! Finance
- Baxter International Inc. (NYSE: BAX) had its price target lowered by analysts at Citigroup Inc. from $37.00 to $35.00. They now have a "neutral" rating on the stock.MarketBeat
BAX
Earnings
- 11/8/24 - Miss
BAX
Sec Filings
- 12/17/24 - Form 4
- 12/4/24 - Form 4
- 12/4/24 - Form 4
- BAX's page on the SEC website